Why Brussels is suing Astrazeneca
Question and answer between the European Commission and Astrazeneca on the supply of the anti Covid vaccine
The clash between the EU Commission and Astrazeneca ends in court. The European Union has started legal actions against the pharmaceutical company because it has not respected certain deadlines for the delivery of the vaccine doses .
All the details.
WHAT THE EU COMMISSION HAS DONE
On Friday, the European Commission filed a lawsuit against Astrazeneca because "the terms of the contract were not met and because the company is unable to apply a reliable strategy to ensure precise and on-time deliveries," a Commission spokesperson announced. .
OBJECTIVE TO ACCELERATE DELIVERIES
For the Commission "it is important, in this case, to ensure the rapid delivery of a sufficient number of doses to which European citizens are entitled and which have been promised to us under the contract", added the spokesperson, according to Agi.
A CAUSE ON BEHALF OF THE 27 STATES
The move is signed by "the 27 member states", which in recent days had been invited by the EU Commission to take part in the legal initiative launched. "According to a diplomatic source, the Commission's Vaccine Steering Committee, in which member states participate, was still asked to sign the action by Friday to allow a request to be filed," reports The Guardian .
DELIVERIES
The Anglo-Swedish company, among the first to sign a purchase contract with the EU Commission, should have delivered around 120 million doses to Europe, and therefore to the Member States, by the first quarter of 2021. The doses arrived for the immunization of the Old Continent, however, stopped at only 30 million.
THE REPLICA OF ASTRAZENECA
The company promises an expedited delivery of 50 million doses, claiming to have respected the agreements.
"AstraZeneca regrets the decision of the European Commission to take legal action for the supply of vaccines against Covid-19," writes Astrazeneca in a statement.
“After an unprecedented year of scientific breakthroughs, very complex negotiations and manufacturing challenges, our company is about to supply nearly 50 million doses to European countries by the end of April, in line with our forecasts,” explains the Anglo-based company. Swedish, which claims to have “fully respected the purchase agreement with the European Commission and will firmly defend itself in court. We believe that any dispute is without merit and welcome this opportunity to resolve this dispute as soon as possible ”.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/perche-bruxelles-fa-causa-ad-astrazeneca/ on Mon, 26 Apr 2021 14:35:23 +0000.